Samsung Biologics

Samsung Biologics completes acquisition of GSK’s manufacturing facility in Rockville, Maryland

Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics’ geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support Plans further investments to add capabilities and strengthen long-term operations at the Rockville site. 31 March 2026 -- Incheon, South Korea and Maryland, US -- Samsung...

Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards

• Reinforcing long-term commitment to embedding sustainability across operations and partnerships• Continuing to support clients in delivering high-quality, life-saving medicines to patients worldwide. 16 March 2026 -- Incheon, South Korea -- Samsung Biologics, a leading contract development and manufacturing organization (CDMO), received recognition at the 2026 CDMO Leadership Awards presented by Outsourced Pharma and Life...

Samsung Biologics signs manufacturing deal with European pharmaceutical company

The company will provide manufacturing services through 2031 in deals worth over USD 668 million Samsung Biologics’ cumulative contract value for 2024 surpasses USD 4 billion with latest deals 20 November 2024 – Incheon, S. Korea – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced a series of manufacturing...
300, Songdo bio-daero, Yeonsu-gu, Incheon, Republic of Korea